No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects

被引:76
作者
Laine, K
Tybring, G
Bertilsson, L
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Dept Med Lab Sci & Technol, Div Clin Pharmacol, S-14186 Huddinge, Sweden
[2] Univ Turku, Dept Pharmacol & Clin Pharmacol, Turku, Finland
关键词
D O I
10.1067/mcp.2000.108949
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Although it is known that the use of oral contraceptives inhibits oxidative drug metabolism, there is little information regarding their effect on CYP2C19 activity. Moreover, earlier reports suggest that there may be differences in CYP2C19 activity between men and women, Objective: We sought to assess the effect of sex and intake of oral contraceptives on CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole. Methods: To determine CYP2C19 activity in white Swedish subjects, 644 subjects previously phenotyped with mephenytoin and 175 subjects phenotyped with omeprazole were investigated. The 8-hour urinary mephenytoin S/R ratio after ingestion of 100 mg mephenytoin and the plasma concentration ratio of omeprazole/hydroxyomeprazole at 3 hours after ingestion of 20 mg omeprazole were used as measures of CYP2C19 activity. Differences in these ratios and in their frequency distributions were then examined among women with and without oral contraceptives and men. In addition, nearly all subjects in the omeprazole group had been genotyped with regard to the CYP2C19*2 (m(1)) allele, Subjects homozygous for the CYP2C19*2 allele were excluded from the study. Results: The median mephenytoin S/R ratio was 2.5-fold higher in the subgroup of women taking oral contraceptives compared with either women not taking oral contraceptives (P <.001) or men (P <.001). Similarly, the mean omeprazole/hydroxyomeprazole ratio was twice as high in the oral contraceptive group compared with women not taking oral contraceptives (P <.001) or men (P <.001). However, no differences were evident between women not taking oral contraceptives and men in either the mephenytoin group (P=.48) or the omeprazole group (P=.77). The oral contraceptive-induced inhibitory effect on CYP2C19 activity was similar between the CYP2C19*1/*1 and *1/*2 genotypes, and they were independent of age. Conclusions: Intake of oral contraceptives significantly inhibits CYP2C19 activity, but there is no true sex-related difference in CYP2C19 activity in healthy, white, Swedish subjects.
引用
收藏
页码:151 / 159
页数:9
相关论文
共 37 条
[1]   POLYMORPHIC HYDROXYLATION OF S-MEPHENYTOIN AND OMEPRAZOLE METABOLISM IN CAUCASIAN AND CHINESE SUBJECTS [J].
ANDERSSON, T ;
REGARDH, CG ;
LOU, YC ;
ZHANG, Y ;
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1992, 2 (01) :25-31
[2]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[3]   SLOW OMEPRAZOLE METABOLIZERS ARE ALSO POOR S-MEPHENYTOIN HYDROXYLATORS [J].
ANDERSSON, T ;
REGARDH, CG ;
DAHLPUUSTINEN, ML ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1990, 12 (04) :415-416
[4]  
*AP AB, 1999, DRUG SAL STAT SWED 1, P126
[5]   THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY [J].
BALIAN, JD ;
SUKHOVA, N ;
HARRIS, JW ;
HEWETT, J ;
PICKLE, L ;
GOLDSTEIN, JA ;
WOOSLEY, RL ;
FLOCKHART, DA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (06) :662-669
[6]   Can oral contraceptive steroids influence the elimination of nifedipine and its primary pryidine metabolite in humans? [J].
Balogh, A ;
Gessinger, S ;
Svarovsky, U ;
Hippius, M ;
Mellinger, U ;
Klinger, G ;
Hoffmann, A ;
Oettel, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (9-10) :729-734
[7]  
BALOGH A, 1995, EUR J CLIN PHARMACOL, V48, P161
[8]   Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].
Bertilsson, L ;
Dahl, ML .
CNS DRUGS, 1996, 5 (03) :200-223
[9]   Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: Comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype [J].
Chang, M ;
Dahl, ML ;
Tybring, G ;
Gotharson, E ;
Bertilsson, L .
PHARMACOGENETICS, 1995, 5 (06) :358-363
[10]   INTERPHENOTYPE DIFFERENCES IN DISPOSITION AND EFFECT ON GASTRIN-LEVELS OF OMEPRAZOLE - SUITABILITY OF OMEPRAZOLE AS A PROBE FOR CYP2C19 [J].
CHANG, M ;
TYBRING, G ;
DAHL, ML ;
GOTHARSON, E ;
SAGAR, M ;
SEENSALU, R ;
BERTILSSON, L .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (05) :511-518